Using Stem Cells to Treat Lung Scarring
Author Information
Author(s): Muacevic Alexander, Adler John R, Silverstein Elena, Richmann Michael, Tyl Delaney, Fiaoni Ashley, Pfeifer Kylie, Moussa Hadi, Treacy Alysia, Vigliotta Mathew, Schepps Michael, Sheth Reena, Barry Patrick
Primary Institution: Nova Southeastern University Dr. Kiran C. Patel College of Osteopathic Medicine
Hypothesis
What are the sources and current uses of MSC therapy in treating adult patients with pulmonary fibrosis?
Conclusion
The use of mesenchymal stem cells (MSCs) in treating pulmonary fibrosis in adults is considered safe, but more research is needed to determine long-term outcomes and efficacy.
Supporting Evidence
- Twenty-nine articles met the inclusion criteria, with eight articles ultimately included in the review.
- Most studies used bone marrow-derived MSCs, but other sources included umbilical, placental, and adipose-derived MSCs.
- Adverse effects were generally mild, with fever and chills being the most common.
- Future studies should focus on larger sample sizes to better understand the efficacy of MSCs in treating pulmonary fibrosis.
Takeaway
Doctors are looking at using special cells called stem cells to help heal lung damage from a disease that makes it hard to breathe.
Methodology
A systematic search was conducted to identify peer-reviewed studies on MSCs for treating pulmonary fibrosis, following PRISMA guidelines.
Potential Biases
Potential bias in study selection and appraisal due to the subjective nature of the review process.
Limitations
The studies included had small sample sizes and varied methodologies, which may affect the reliability of the results.
Participant Demographics
Participants varied in age from 33 to 90 years, with a mix of males and females.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website